Search

Your search keyword '"Shimada, Mitsuo"' showing total 2,894 results
Start Over Author "Shimada, Mitsuo"
2,894 results on '"Shimada, Mitsuo"'

12. A novel scoring system to predict short-term mortality after living donor liver transplantation for acute liver failure

Author

Sudhindran, Surendran, Yoshizumi, Tomoharu, Hatano, Etsuro, Okumura, Shinya, Hasegawa, Kiyoshi, Egawa, Hiroto, Obara, Hideaki, Yasui, Kazuya, Ogura, Yasuhiro, Jobara, Kanta, Nitta, Hiroyuki, Katagiri, Hirokatsu, Otsuka, Masayuki, Kuboki, Satoshi, Eguchi, Susumu, Hara, Takanobu, Eguchi, Hidetoshi, Sasaki, Kazuki, Aoki, Taku, Ohdan, Hideki, Ohira, Masahiro, Takada, Yasutsugu, Ogawa, Kohei, Fukumoto, Takumi, Kuramitsu, Kaori, Saiura, Akio, Ichida, Hirofumi, Hashimoto, Takuya, Marubashi, Shigeru, Sato, Naoya, Ushigome, Hidetaka, Harada, Shumpei, Soejima, Yuji, Masuda, Yuichi, Shimada, Mitsuo, Saitou, Yu, Taketomi, Akinobu, Goto, Ryoichi, Shimamura, Tsuyoshi, Mizuno, Shugo, Tanemura, Akihiro, Endo, Itaru, Unno, Michiaki, Miyagi, Shigehito, Okamura, Yukiyasu, Aramaki, Osamu, Hakamada, Kenichi, Ishido, Keinosuke, Kato, Yutaro, Takahara, Takeshi, Takatsuki, Mitsuhisa, Ono, Shinichiro, Shimata, Keita, Yoon, Young-In, Hibi, Taizo, Morinaga, Jun, Narayanan, Anila Kutty, Toshima, Takeo, Ito, Takashi, Akamatsu, Nobuhisa, Kotera, Yoshihito, Hong, Suk Kyun, Hasegawa, Yasushi, Umeda, Yuzo, Reddy, Mettu Srinivas, Ong, Aldwin De Leon, Sivaprasadan, Saraswathy, Varghese, Joy, Sugawara, Yasuhiko, Chen, Chao-Long, Nakayama, Nobuaki, Mochida, Satoshi, Tanaka, Atsushi, Suh, Kyung-Suk, Ikegami, Toru, Lee, Kwang-Woong, and Lee, Sung-Gyu

Published
2024
Full Text
View/download PDF

16. Lineage of drug discovery research on fluorinated pyrimidines: chronicle of the achievements accomplished by Professor Setsuro Fujii

Author

Maehara, Yoshihiko, Oki, Eiji, Ota, Mitsuhiko, Harimoto, Norifumi, Ando, Koji, Nakanishi, Ryota, Kawazoe, Tetsuro, Fujimoto, Yoshiaki, Nonaka, Kentaro, Kitao, Hiroyuki, Iimori, Makoto, Makino, Kunio, Takechi, Teiji, Sagara, Takeshi, Miyadera, Kazutaka, Matsuoka, Kazuaki, Tsukihara, Hiroshi, Kataoka, Yuki, Wakasa, Takeshi, Ochiiwa, Hiroaki, Kamahori, Yoshihiro, Tokunaga, Eriko, Saeki, Hiroshi, Yoshizumi, Tomoharu, Kakeji, Yoshihiro, Shirabe, Ken, Baba, Hideo, and Shimada, Mitsuo

Published
2023
Full Text
View/download PDF

26. Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3 trial

Author

Thompson, Alexander, Danta, Mark, Poursoltan, Pirooz, Kiberu, Andrew, Chittajallu, Renuka, Sood, Siddarth, Stauber, Rudolf, Pinter, Matthias, Peck-Radosavljevic, Markus, Decaestecker, Jochen, Cuyle, Pieter-Jan, Verset, Gontran, Van Vlierberghe, Hans, De Azevedo, Sergio, Andrade, Livia, Cunha Júnior, Ademar, Faria, Luiza, Yen, Cheng Tzu, Colli, Leandro, Asselah, Jamil, Kavan, Petr, Marquez, Vladimir, Brahmania, Mayur, Li, Qiang, Xing, Baocai, Guo, Yabing, Chen, Zhendong, Zhao, Haitao, Peng, Tao, Wang, Liming, Wang, Lu, Liu, Hongming, Wu, Feixiang, Qin, Lunxiu, Zheng, Qichang, Ying, Jieer, Li, Haitao, Wen, Tianfu, Qin, Shukui, Wen, Xiaoyu, Liu, Yunpeng, Chen, Minshan, Wang, Boqing, Bai, Yuxian, He, Yifu, Zhao, Hong, Zhou, Dong, Dai, Chaoliu, Teng, Gaojun, Cui, Shuzhong, Gao, Yi, Zhang, Xizhi, Lu, Zheng, Yin, Tao, Ding, Youming, Jia, Weidong, Xia, Yongxiang, Sun, Beicheng, Xia, Qiang, Yuan, Yufeng, Sun, Huichuan, Shi, Xuetao, Guzmán, Adrián, Corrales, Luis, Kral, Zdenek, Priester, Peter, Kubala, Eugen, Blanc, Jean Frederic, Bourliere, Marc, Peron, Jean Marie, Borg, Christophe, Bronowicki, Jean-Pierre, Ganne, Nathalie, Decaens, Thomas, Uguen, Thomas, Heurgue, Alexandra, Trojan, Joerg, Gonzalez-Carmona, Maria Angeles, Roderburg, Christoph, Ettrich, Thomas, Schotten, Clemens, Kandulski, Arne, Yau, Thomas, Chan, Lam, Scartozzi, Mario, Masi, Gianluca, Fanello, Silvia, Battezzati, Pier Maria, Leonardi, Francesco, Ghidini, Michele, Numata, Kazushi, Morimoto, Manabu, Hidaka, Hisashi, Tsuchiya, Kaoru, Yamashita, Tatsuya, Kato, Naoya, Kudo, Masatoshi, Hagihara, Atsushi, Koga, Hironori, Arakawa, Tomohiro, Nakamura, Ikuo, Kawamura, Yusuke, Kawaoka, Tomokazu, Shimada, Mitsuo, Hasegawa, Kiyoshi, Marusawa, Hiroyuki, Nakamura, Shinchiro, Hiraoka, Atsushi, Hayashi, Hiromitsu, Takeda, Shin, Lee, Han Chu, Paik, Seung Woon, Kim, Do Young, Lee, Jung Il, Jeong, Sook-Hyang, Kim, Won, Tak, Won Young, Heo, Jeong, Kim, Hyeyeong, Chon, Hong Jae, Cheong, Jaeyoun, Yoon, Seung Kew, Yoon, Jung-Hwan, Villalobos, Ricardo, Martinez Rodriguez, Jorge Luis, Oyervides Juarez, Victor, Hernández, Carlos Alberto, Klumpen, Heinz-Josef, de Vos-Geelen, Judith, Gane, Edward, Montenegro, Paola, Torres Mattos, Cesar, Janczewska, Ewa, Kawecki, Maciej, Nowakowska-Zajdel, Ewa, Fedenko, Alexander, Granov, Dmitrii, Alyasova, Anna, Sekacheva, Marina, Ledin, Evgeny, Samol, Jens, Toh, Han Chong, Calvo Campos, Mariona, Gomez Martin, Carlos, Lopez Lopez, Carlos, Muñoz Martin, Andres Jesus, Calleja Panero, Jose Luis, Montero Alvarez, Jose Luis, Reig Monzón, Maria, Delgado Mingorance, Ignacio, Minguez Rosique, Beatriz, Cheng, Ann Lii, Huang, Yi-Hsiang, Lin, Shi-Ming, Huang, Jee-Fu, Yu, Ming-Lung, Su, Wei-Wen, Korphaisarn, Krittiya, Maneenil, Kunlatida, Samdaengpan, Chayanee, Tharavichitkul, Ekkapong, Ozguroglu, Mustafa, Kose, Fatih, Harputluoglu, Hakan, Buchschacher, Gary, Thuluvath, Paul, Xiong, Henry, Patel, Mital, Gold, Philip, Li, Daneng, Brooks, Gabriel, Masood, Ashiq, Patel, Reema, George, Ben, Salgia, Reena, Manji, Gulam, Crow, Mary, Kaseb, Ahmed, Dugan, Matthew, Kadakia, Kunal, Kardosh, Adel, Gibbs, John, Shah, Ashesh, Burris III, Howard, Hsiehchen, David, Cheng, Ann-Lii, Kaseb, Ahmed O, Yopp, Adam C, Zhou, Jian, Nakamura, Shinichiro, Cha, Edward, Hack, Stephen P, Lian, Qinshu, Ma, Ning, Spahn, Jessica H, Wang, Yulei, Wu, Chun, and Chow, Pierce K H

Published
2023
Full Text
View/download PDF

28. Impact of the hospital volume and setting on postoperative complications of surgery for gastroenterological cancers in a regional area of Western Japan

Author

Kunisawa, Susumu, Ishida, Haku, Ikai, Hiroshi, Nagano, Hiroaki, Fujiwara, Toshiyoshi, Ohdan, Hideki, Fujiwara, Yoshiyuki, Tajima, Yoshitsugu, Ueno, Tomio, Fujiwara, Yoshinori, Shimada, Mitsuo, Suzuki, Yasuyuki, Watanabe, Yuji, Hanazaki, Kazuhiro, Kakeji, Yoshihiro, Kumamaru, Hiraku, Takahashi, Arata, Miyata, Hiroaki, and Imanaka, Yuichi

Published
2023
Full Text
View/download PDF

37. A randomized controlled trial of surgery and postoperative modified FOLFOX6 versus surgery and perioperative modified FOLFOX6 plus cetuximab in patients with KRAS wild-type resectable colorectal liver metastases: EXPERT study

Author

Matsumura, Masaru, Hasegawa, Kiyoshi, Oba, Masaru, Yamaguchi, Kensei, Uetake, Hiroyuki, Yoshino, Takayuki, Morita, Satoshi, Takahashi, Keiichi, Unno, Michiaki, Shimada, Yasuhiro, Muro, Kei, Matsuhashi, Nobuhisa, Mori, Masaki, Baba, Hideo, Shimada, Mitsuo, Mise, Yoshihiro, Kawaguchi, Yoshikuni, Kagimura, Tatsuo, Ishigure, Kiyoshi, Saiura, Akio, Sugihara, Kenichi, and Kokudo, Norihiro

Published
2022
Full Text
View/download PDF

41. Lenvatinib‐resistant hepatocellular carcinoma promotes malignant potential of tumor‐associated macrophages via exosomal miR‐301a‐3p.

Author

Waki, Yuhei, Morine, Yuji, Saito, Yu, Teraoku, Hiroki, Yamada, Shinichiro, Ikemoto, Tetsuya, Tominaga, Tatsuya, and Shimada, Mitsuo

Subjects
GENE expression, GASTROINTESTINAL cancer, BIOINFORMATICS software, HEPATOCELLULAR carcinoma, DRUG resistance
Abstract

Background: The interactions between cancer cells and tumor‐associated macrophages (TAMs) via microRNAs (miRNAs) play crucial roles in malignant potential and drug resistance. However, it remains unclear how lenvatinib‐resistant hepatocellular carcinoma (LR HCC) promotes TAM tumor biology. Here we investigated the crosstalk between LR HCC cells and TAMs for cancer progression and lenvatinib resistance, focusing on an exosomal miRNA. Methods: We used two bioinformatics software programs to identify miRNAs that target PTEN in gastrointestinal cancers, then investigated exosomal miRNA expression in LR HCC conditioned medium (CM). After modifying TAMs with LR HCC CM (LR TAM), macrophage phenotype and PTEN‐Nrf2 signaling pathway component expression were analyzed in LR TAMs. The malignant potential and drug resistance were investigated in naïve HCC cells cultured with LR TAM CM. Results: LR HCC cells highly induced M2‐like properties in macrophages compared with naïve HCC cells. Exosomal miR‐301a‐3p expression was increased in LR HCC CM, with higher activation of the PTEN/PI3K/GSK3β/Nrf2 signaling pathway in LR TAMs. Naïve HCC cells were educated with LR TAM CM to promote malignant potential and lenvatinib resistance. Inhibition of exosomal miR‐301a‐3p prevented the malignant potential of LR TAMs. Activation of Nrf2 signaling by LR HCC cell‐derived exosomal miR‐301a‐3p skewed the transformation of macrophages to the M2 phenotype. Conclusion: Our study provides new findings on the role of miR‐301a‐3p, suggesting it is a promising therapeutic target to improve HCC lenvatinib resistance. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

42. Impact of robotic gastrectomy in patients with primary T3 or more advanced gastric cancer.

Author

Nishi, Masaaki, Takasu, Chie, Wada, Yuma, Yoshikawa, Kozo, Tokunaga, Takuya, Nakao, Toshihiro, Kashihara, Hideya, Yoshimoto, Toshiaki, and Shimada, Mitsuo

Subjects
LYMPHADENECTOMY, MINIMALLY invasive procedures, SURGICAL robots, LAPAROSCOPIC surgery, STOMACH cancer
Abstract

Background: The use of robotic surgery (RS) for gastric cancer (GC) has been rapidly increasing. However, the utility of RS for advanced GC (AGC), especially T3 or more AGC, is unclear. Methods: Ninety patients who underwent curative upfront minimally invasive surgery (MIS) (D2 lymph node dissection) for fStage II or III GC were enrolled in this study. Among these patients, 68 underwent MIS for T3 or more AGC. Thirty‐six patients underwent RS, and 32 patients underwent laparoscopic surgery (LS). The short‐term and long‐term surgical outcomes were compared between the two groups. Results: In the T3 or more AGC cohort, there were no significant intergroup differences in the operative time or blood loss volume. The number of retrieved lymph nodes tended to be higher in the RS than LS group (38.5 vs. 33.0, p =.11). The drain amylase content on postoperative day 1 was significantly lower in the RS than LS group (243.5 vs. 521.0 IU/L, p <.01). The morbidity rate (Clavien–Dindo grade ≥2) was similar between the groups. There were no significant differences between the LS and RS groups in the 3‐year overall survival rate (80.7% vs. 74.5%, respectively; p =.95) or 3‐year disease‐free survival rate (75.0% vs. 69.7%, respectively; p =.95). Conclusions: RS for primary T3 or more AGC was safe and contributed to similar short‐term and long‐term outcomes compared with LS. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results